Martindale Pharma launches first ready-to-use presentation of phenylephrine

Phenylephrine available in new presentation strength of 0.1mg/ml to maximise accuracy and flexibility of dosing

Martindale Pharma, has announced the UK launch of phenylephrine, a new strength of the selective vasopressor drug for the treatment of hypotension associated with anaesthesia. From today, phenylephrine will be available in a 10ml ampoule at a strength of 0.1mg/ml.

This new strength not only allows for accurate dose dispensing but also provides healthcare professionals with a replacement to using the concentrated alternative. To date phenylephrine is only available as a 10mg/ml in 1ml ampoules, which is diluted prior to use. Martindale Pharma’s phenylephrine product can be given as an intravenous bolus injection or as a continuous infusion without the need for dilution.

Michael Clark, chief marketing officer of Martindale Pharma, commented: “We are pleased with this positive addition to this well-known phenylephrine range. Our novel presentation removes the need to dilute the drug prior to use allowing for more accurate dose dispensing resulting in both time and cost savings for the NHS.”